Edwin M. O'Connor

Edwin M. O'Connor

Edwin O’Connor, a partner in Goodwin’s Technology Companies Group, has a broad-based capital markets practice and represents issuers and underwriters in public and private corporate finance transactions, both in the United States and internationally. His experience encompasses initial public offerings, follow-on equity offerings, investment grade, high-yield and convertible debt offerings and offerings of preferred, hybrid and derivative securities. He has particular experience with capital markets transactions in the tech, life sciences and clean tech sectors.

Professional Experience

Prior to joining Goodwin in 2014, Mr. O’Connor practiced at Gibson, Dunn & Crutcher. Previously, he was a vice president in the Investment Banking Division of Goldman, Sachs & Co., where he was responsible for the execution of equity and equity-linked offerings across all industry sectors. While at Goldman, Mr. O’Connor was also a vice president, associate general counsel in the Investment Banking Division’s Legal Group. At Goldman, he worked on transactions occurring in a number of geographies, including New York, Silicon Valley, London and Hong Kong. Before joining Goldman, he was an associate at Davis Polk & Wardwell in New York and in London.


In law school, Mr. O’Connor served as comments editor of The Journal of International Economic Law.

Areas of Practice


Mr. O’Connor has recently represented:

  • Morgan Stanley & Co. LLC and Piper Jaffray & Co. as joint book-running managers in a $40 million follow-on offering for Innocoll
  • Citigroup Global Markets Inc. and Cowen and Company, LLC as joint book-running managers in Reata Pharmaceuticals' $60.5 million initial public offering
  • Jefferies LLC and Barclays Capital Inc. as joint book-running managers in Oncobiologics' $35 million initial public offering, BeiGene in its $158 million initial public offering
  • Voyager Therapeutics in its $70 million initial public offering
  • Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, Barclays Capital Inc. and Leerink Partners LLC, as joint book-running managers in the $281.5 million follow-on offering for DBV Technologies
  • Morgan Stanley & Co. LLC, Citigroup Global Markets Inc., Cowen and Company, LLC and Jefferies LLC, as joint book-running managers in a $162 million secondary public offering by existing shareholders for Horizon Pharma, Inc.
  • Inotek Pharmaceuticals Corporation in its $40 million initial public offering and a concurrent offering of $20 million offering of convertible senior notes, its $69 million follow-on offering and its $50 million offering of convertible senior notes
  • Goldman Sachs and other underwriters in Trinseo’s $190 million initial public offering*
  • Barclays and J.P. Morgan in Paycom Software’s $100 million initial public offering*

As Vice President in Goldman Sachs’ Investment Banking Division, Mr. O’Connor advised on several initial public offerings, including:

  • Cornerstone OnDemand’s $137 million IPO
  • RPX’s $160 million IPO
  • Gigamon’s $128.5 million IPO
  • Jive’s $120 million IPO
  • Palo Alto Network’s $260 million IPO

 *Denotes experience prior to joining Goodwin Procter



J.D., 1998
University of Pennsylvania Law School
B.A., Economics, 1995
Colgate University
(magna cum laude; Phi Beta Kappa)



New York
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers